The Liver Meeting® 2018 ePosters: Hepatitis C
-
LB-15: Sofosbuvir/Velpatasvir for 12 Weeks Is Safe and Effective in Patients Undergoing DialysisAuthors: Robert Hyland, Sergio BorgiaYou must log in to access content.
-
LB-34: Response-Guided Therapy with Direct-Acting Antivirals Shortens Treatment Duration in 50% of HCV Treated PatientsAuthor: Ohad EtzionYou must log in to access content.
-
582: Evolution of Estimated Glomerular Filtration Rate (eGFR) in Patients with Chronic Hepatitis C Receiving Sofosbuvir-Containing or Sofosbuvir-Free Direct Acting Antiviral AgentsAuthors: Chen-Hua Liu, Mei-Hsuan Lee, Chun-Jen Liu, Tung-Hung Su, Chun-Ming Hong, Tai-Chung Tseng, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng KaoYou must log in to access content.
-
583: Retreatment with SOF/VEL/VOX in Treatment-Experienced Patients with and without HIV: The Resolve StudyAuthors: Emily Covert, Eleanor Wilson, Jenny Hoffmann, Emily Comstock, Lydia Tang, Sarah Kattakuzhy, Elana Rosenthal, Poonam Mathur, Henry Masur, Shyam Kottilil, Benjamin EmmanuelYou must log in to access content.
-
586: Real-World Impact of Resistance-Associated Substitutions on Re-Treatment after Ledipasvir/Sofosbuvir Virologic Failure in Hepatitis C PatientsAuthors: Lisa Backus, Pamela Belperio, Troy Shahoumian, Timothy Loomis, Mark Winters, Mark HolodniyYou must log in to access content.
-
587: Artificial Intelligence (AI) Accurately Predicts the Daa-Treatment Outcomes Using Algorithms from Unique Variants of HCV.Authors: Hiroaki Haga, Yoshiyuki Ueno, Hidenori Sato, Kazuo Okumoto, Kyoko Tomita, Kei Mizuno, Taketo Nishina, Ayumi Koseki, Takafumi SaitoYou must log in to access content.
-
589: Risk of Incident Diabetes in Hepatitis C Patients Following Completion of Direct-Acting Antiviral TherapyAuthors: Anu Osinusi, Amanda Singer, Diana Brainard, Laura Telep, Anand ChokkalingamYou must log in to access content.
-
595: Sustained Viral Response Following Treatment with Direct Acting Antiviral Regimens Is Durable in More Than 6,600 Patients: Results of the Gilead Sustained Virologic Response Registry StudyAuthors: Christian Schwabe, Robert Hyland, Eric Lawitz, Stanislas Pol, Stephen Shafran, Frances Chen, Hadas Dvory-Sobol, Anu Osinusi, Diana Brainard, Christophe Moreno, Alessio Aghemo, Simone Strasser, Stefan ZeuzemYou must log in to access content.
-
596: Greater Cumulative Exposure to HIV Viremia Predicts Hepatocellular Carcinoma Occurrence in HIV Patients after Direct-Acting Antivirals for HCV.Authors: Viola Guardigni, Alberto Casabianca, Lorenzo Badia, Gabriella Verucchi, Pierluigi Viale, Simona ColadonatoYou must log in to access content.
-
598: High Efficacy of Interferon-Free Therapy for Acute Hepatitis C in HIV-Positive PatientsAuthors: David Chromy, Mattias Mandorfer, Theresa Bucsics, Philipp Schwabl, Bernhard Scheiner, Caroline Schmidbauer, Maximilian Aichelburg, Peter FerenciYou must log in to access content.
-
601:Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Pangenotypic Treatment of Chronic Hepatitis C: Results from a Spanish Cohort (Hepa-C)Authors: Javier Salmeron, Manuel Nicolas Hernandez Guerra, Agustin Albillos, Marc Puigvehi, Inmaculada Fernandez, Martín Prieto, Xavier Torras Collell, Jose Miguel Rosales Zabal, Lourdes Grande, Rosa Morillas, Moises Diago, Beatriz De Cuenca, Manuel Delgado, Lucia Bonet, Juan Turnes, Javier Crespo, Carme Baliellas, Jose Luis Calleja, Ester Badia, Juan Manuel Pascasio, Jose Maria Moreno Planas, Vanesa Bernal, Isabel Carmona, Miguel Fernandez, Pablo Bellot, Jesus M. Gonzalez-Santiago, Maria Gutierrez, J.Javier Moreno, Maria Dolores Anton, Juan De La Vega, Desamparados Escudero-Garcia, Juan Arenas, Jose Antonio Carrion, Ana ViuYou must log in to access content.
-
602: Durability of Sustained Virologic Response and Liver Safety in Patients Treated with Glecaprevir/Pibrentasvir: A Long-Term Follow-up StudyAuthors: Franco Felizarta, Armen Asatryan, Humberto Aguilar, Fred Poordad, Kosh Agarwal, Frederik Nevens, Tarek Hassanein, Graham Foster, Reem Ghalib, David Shaw, David Pugatch, Sandra Lovell, Teresa (Iok Chan) Ng, Federico Mensa, Edward GaneYou must log in to access content.
-
603: Factors Associated with Lack of Improvement in Fibrosis Following HCV TreatmentAuthors: Vishnu Kommineni, Omar Sims, Chiu Chia-Ying, Mohamed Shoreibah, Paul Fitzmorris, John Romano, Moustafa Massoud, Krishna Venkata, Omar MassoudYou must log in to access content.
-
604: Short-Duration Sofosbuvir/Velpatasvir Safe and Effective in Treating HCV Infection Immediately after Liver TransplantAuthors: Edward Gane, Andrea Beckmann, Robert Hyland, Sarah Arterburn, Evguenia Svarovskaia, Benedetta Massetto, Diana Brainard, Stephen MunnYou must log in to access content.
-
605: Glecaprevir/Pibrentasvir Administered for 8 Weeks Results in Excellent Effectiveness and Safety: A Real-Life Study on 639 Italian HCV Patients from the Navigator Lombardia NetworkAuthors: Roberta D'Ambrosio, Luisa Pasulo, Massimo Puoti, Monica Schiavini, Mauro Vigano, Maria Vinci, Barbara Menzaghi, Caterina Valeria Uberti Foppa, Massimo Zuin, Alessandro Soria, Angiola Spinetti, Alessio Aghemo, Maria Grazia Rumi, Angelo Pan, Ombretta Spinelli, Antonella D'Arminio Monforte, Andrea Capretti, Agostino Colli, Alberto Eraldo Colombo, Giancarlo Spinzi, Riccardo Centenaro, Elisabetta Buscarini, Roberta Soffredini, Marta Borghi, Maria Colpani, Sergio Lazzaroni, Franco Maggiolo, Andrea Gori, Paolo Del Poggio, Alessia Giorgini, Lorenzo Morini, Marie Graciella Pigozzi, Omar Giglio, Clara Dibenedetto, Carlo Federico Magni, Franco Noventa, Pietro Lampertico, Stefano Fagiuoli, Massimo MemoliYou must log in to access content.
-
606: Effectiveness of Sofosbuvir/Velpatasvir for 12 Weeks in HCV Genotype 3 Patients with Compensated Cirrhosis in Clinical Practice Cohorts from Around the WorldAuthors: Stefano Fagiuoli, Kosh Agarwal, Alessandra Mangia, Stephen Shafran, Heiner Wedemeyer, Jordan Feld, Juan Turnes, Peter Buggisch, Alessia Ciancio, Sergio Borgia, Stefan Christensen, Johannes Vermehren, Scott Milligan, Gail Matthews, Alnoor Ramji, Stanislas Pol, Denis Ouzan, John Wolf, Michael Mertens, Phil Troke, Andrew Ustianowski, Norah TerraultYou must log in to access content.
-
607: Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Prior Treatment Failures with Glecaprevir/Pibrentasvir (G/P) in Chronic Hepatitis C InfectionAuthors: Brian Pearlman, Andrew Hinds, Michael PerrysYou must log in to access content.
-
608: Effectiveness of Sofosbuvir / Velpatasvir in Treating Hepatitis C Virus Infection in Real-World SettingAuthors: Naveed Janjua, Stanley Wong, Amanda Yu, Darrel Cook, Zahid Butt, Carmine Rossi, Maria Alvarez, Mawuena Binka, Maryam Darvishian, Nuria Chapinal, Eric Yoshida, Alnoor Ramji, Mel Krajden, Mark TyndallYou must log in to access content.
-
609: The cT1 Multi-Parametric MRI Value Is More Sensitive and Reliable Than Transient Elastography for the Non-Invasive Monitoring of Intra-Hepatic Inflammation/Fibrosis Response to Daa Therapy in CHC PatientsAuthors: Antonio Salvati, Nicola Martini, Andy Mckay, Barbara Coco, Piero Colombatto, Gabriele Ricco, Filippo Oliveri, Veronica Romagnoli, Francesco Faita, Ferruccio Bonino, Dante Chiappino, Maurizia BrunettoYou must log in to access content.
-
610: Impact of Baseline HCV RNA Levels As Assessed By 2 Assays on the Efficacy of 8-Week Glecaprevir/Pibrentasvir in Patients with HCV GT1-6 InfectionAuthors: Heiner Wedemeyer, Shyam Kottilil, Douglas Dylla, Marc Bourliere, Christoph Sarrazin, James Levin, Armen Asatryan, Yiran Hu, Mitchell ShiffmanYou must log in to access content.
Access Date | Quiz Result | Score | Actions |
---|